Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1242 daily bars · split adjusted
Current price $38.61
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 10, 26 | Benchmark |
Daily · Wilder smoothing
| downgrade |
| Buy |
| Hold |
| Jul 27, 26 | Stephens & Co. | downgrade | Overweight | Equal Weight |
| Jul 23, 26 | TD Cowen | downgrade | Buy | Hold |
| Jul 23, 26 | Jefferies | downgrade | Buy | Hold |
| Jul 22, 26 | HC Wainwright & Co. | downgrade | Buy | Neutral |
| Jul 22, 26 | Lake Street | downgrade | Buy | Hold |
| Dec 29, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 24, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 8, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-07
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 60.55 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 59.96 | Oscillator | Neutral |
| Williams %R (14) | -32.30 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.84 (Hist -0.05) | Oscillator | Sell |
| Average Directional Index (14) | 40.47 (+DI 26.4 / -DI 15.9) | Trend | Strong Buy |
| EMA 20 | 37.48 | MA | Strong Buy |
| SMA 20 | 37.24 | MA | Strong Buy |
| EMA 50 | 35.42 | MA | Strong Buy |
| SMA 50 | 35.87 | MA | Strong Buy |
| SMA 200 | 26.69 | MA | Strong Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 6, 26 | Wichterman Troy | officer: Chief Financial Officer | A-Award | 62,300 | — |
| Oct 6, 26 | Wichterman Troy | officer: Chief Financial Officer | A-Award | 76,204 | — |
| Oct 6, 26 | Wichterman Troy | officer: Chief Financial Officer | F-InKind | 95,933 @ $38.61 | $3.70M |
| Oct 6, 26 | Wichterman Troy | officer: Chief Financial Officer | D-Return | 256,000 @ $11.25 | $2.88M |
| Oct 6, 26 | Goswami Joydeep | director | D-Return | 53,156 @ $11.25 | $598.0K |
| Oct 6, 26 | Ellingson Rachel | director | D-Return | 57,995 @ $11.25 | $652.4K |
| Oct 6, 26 | Duross Amy | director | D-Return | 26,857 @ $11.25 | $302.1K |
| Oct 6, 26 | Coste Catherine | director | D-Return | 13,871 @ $11.25 | $156.0K |
TTM vs. 5-year historical average (annual ratios)
| Metric | BLFS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 37.3x | -68.2x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 64.4x | EPS est. 0.60 | Elevated |
| Price / Book | 4.5x | 2.8x | Elevated |
| Price / Sales | 18.3x | 11.8x | Elevated |
| EV / EBITDA | 194.9x | 202.5x | In line |
| Return on equity | 13.3% | — | Healthy |
| Gross margin | 64.5% | 56.6% | In line |
| Debt / Equity | 0.04 | 0.08 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 40.85 | Safe zone |
Discounted cash flow model
FY2024 · 10-K disclosure
Stock news · updated daily
On October 23, 2026, BioLife Solutions Inc (BLFS) shares rose 3.5% to a current price of $38.61. The stock has shown a 52-week range between $17.86 and $39.76,
BioLife Solutions NASDAQ: BLFS stockholders approved the company's merger agreement with Repligen Corporation at a special meeting held virtually on Oct. 5, 2026, clearing a key shareholder-vote requirement for the proposed transaction.
Shares of BioLife Solutions, Inc. (NASDAQ: BLFS - Get Free Report) have earned an average rating of "Hold" from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Ten analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price objective
Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026Insiders may stand to receive substantial financial be
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether t.
Bank of New York Mellon Corp bought a new position in shares of BioLife Solutions, Inc. (NASDAQ: BLFS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 229,109 shares of the medical equipment provider's stock, valued at
BioLife Solutions (NASDAQ: BLFS - Get Free Report) and Qiagen (NYSE: QGEN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Institutional and Insider Ownership 93.2% of BioLife Solutions shares
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | 0.03 | 0.91 | Beat 2812.0% | $28.47M |
| May 7, 2026 | 0.01 | 0.04 | Beat 300.0% | $27.50M |
| Feb 26, 2026 | -0.02 | 0.04 | Beat 300.0% | $24.76M |
| Nov 6, 2025 | 0.00 | 0.04 | Beat 1900.0% | $28.10M |
| Aug 7, 2025 | -0.02 | -0.33 | Miss -1550.0% | $25.42M |
| May 8, 2025 | -0.03 | 0.04 | Beat 233.3% | $23.94M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 15-12G | Oct 16, 2026 | 2026-10-16 16:00:08 | View |
| EFFECT | Oct 9, 2026 | 2026-10-13 00:15:04 | View |
| EFFECT | Oct 9, 2026 | 2026-10-13 00:15:03 | View |
| 4 | Oct 8, 2026 | 2026-10-08 21:59:35 | View |
| 4 | Oct 8, 2026 | 2026-10-08 21:59:33 | View |
| 4 | Oct 8, 2026 | 2026-10-08 21:59:10 | View |
| 4 | Oct 8, 2026 | 2026-10-08 21:59:00 | View |
| 4 | Oct 8, 2026 | 2026-10-08 21:58:49 | View |
| 4 | Oct 8, 2026 | 2026-10-08 21:58:27 | View |
| 4 | Oct 8, 2026 | 2026-10-08 21:58:14 | View |
Proxy statement (DEF 14A) disclosures